Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Vitamin D is important in bone metabolism.
Studies have suggested that vitamin D may lower the risk of developing certain cancers and provide benefit in several diseases, although a causal relationship has yet to be established through clinical trials.
Adequate vitamin D levels can be maintained with oral supplementation.
Because of known side effects of unprotected exposure to natural and artificial UV radiation, using UV exposure as a means of obtaining adequate serum vitamin D levels should be discouraged.
Vitamin D is a fat-soluble prohormone that plays an important role in calcium and phosphorus homeostasis as well as in many organ systems throughout the body. There are two major physiologically relevant forms of vitamin D: D 2 (ergocalciferol) and D 3 (cholecalciferol). Vitamin D 2 , which is present in yeast and mushrooms, is derived from ergosterol, a yeast and plant sterol. Vitamin D 3 is produced photochemically in the skin from 7-dehydrocholesterol, a cholesterol precursor.
The modern history of vitamin D began in the mid-1800s, when it was noticed that city children were more likely to have rickets than rural children. Half a century later, Palm reported that children raised in sunny climates virtually never developed rickets. McCollum isolated vitamin D, and Windaus its precursors, receiving the Nobel Prize.
In humans, vitamin D is obtained naturally through two sources, diet and sunlight. Very few foods inherently contain significant amounts of vitamin D. Fatty fish like salmon, tuna, and mackerel, as well as fish liver oils are among the best sources, providing 200 to 1600 IU per serving. Beef liver, cheese, and egg yolks provide small amounts of vitamin D – 12 to 20 IU per serving – and some mushrooms contain variable amounts. The majority of dietary vitamin D in countries like the United States and Canada comes from foods such as milk, milk products, juices, and cereal products that are fortified with vitamin D. One 8 ounce serving of fortified milk or orange juice in the United States provides approximately 100 IU of vitamin D ( Table 60.1 ).
Food | International Units (IU) per Serving |
---|---|
Atlantic herring, 3.5 ounces | 1600 |
Cod liver oil, 1 tablespoon | 1360 |
Mushrooms, enriched with vitamin D, 3 ounces | 400 |
Salmon, 3.5 ounces | 360 |
Mackerel, 3.5 ounces | 345 |
Sardines, canned in oil, drained, 1.75 ounces | 250 |
Tuna fish, canned in oil, 3 ounces | 200 |
Orange juice fortified with vitamin D, 1 cup (amount of added vitamin D varies) | 142 |
Milk, non-fat, reduced fat, and whole, vitamin D fortified, 1 cup | 98 |
Margarine, fortified, 1 tablespoon | 60 |
Ready-to-eat cereal, fortified, 0.75–1 cup (amount of added vitamin D varies) | 40 |
Egg, 1 whole (vitamin D is found in yolk) | 20 |
Liver, beef, 3.5 ounces | 15 |
Cheese, Swiss, 1 ounce | 12 |
The major natural source of vitamin D in humans is from the exposure of skin to sunlight. UVB radiation is absorbed by cutaneous 7-dehydrocholesterol to form pre-vitamin D 3 ( Fig. 60.1 ). This process largely occurs in the stratum basale and stratum spinosum, where 7-dehydrocholesterol is the most concentrated. Pre-vitamin D 3 undergoes a temperature-dependent isomerization to form vitamin D 3 , which is then hydroxylated by the liver to 25-hydroxyvitamin D [25(OH)D] via the 25-hydroxylase enzyme. An additional hydroxylation by the kidney via the 1α-hydroxylase enzyme is necessary to produce the physiologically active vitamin D metabolite, 1α,25-dihydroxyvitamin D [1,25(OH) 2 D], which is best known for promoting intestinal absorption of calcium and phosphorus, decreasing their clearance from the kidney, and promoting bone mineralization.
In addition to foods and sunlight, vitamin D is also available in supplement form as D 2 or D 3 . Comparisons between the two forms have shown D 2 to have a shorter shelf-life, diminished binding of its metabolites to vitamin D binding protein in plasma, and less efficacy in raising and maintaining serum vitamin D metabolite levels. Given these findings, vitamin D 3 is preferred to D 2 for supplementation.
Minimal winter sunlight exposure reaches the lower epidermal layers, and therefore little vitamin D is produced in the wintertime. Melanin, which is produced by melanocytes located in the stratum basale, also affects the quantity of vitamin D produced by absorbing UVB. Melanin concentration determines the amount of UVB that can interact with the 7-dehydrocholesterol in the lower epidermal layers, though it does not change the capacity to produce vitamin D; individuals with darker skin pigmentation may need three to six times longer exposure to produce the same amount of pre-vitamin D as those with fair skin. Skin from older individuals contains less substrate for pre-vitamin D synthesis, and they may produce up to four times less pre-vitamin D than their younger counterparts.
Though 25(OH)D has low biological activity, its serum concentration, which can be measured in commercial laboratories, is the most widely used biomarker for an individual's vitamin D status. 25(OH)D levels have been correlated with important health endpoints ( Table 60.2 ); the levels are commonly reported as either nmol/L or ng/mL ( Table 60.3 ). One complication in determining vitamin D status is that there is variability among the laboratories that conduct the analyses as well as in the various available assays. However, a new standard reference material for 25(OH)D became available in July 2009, which should allow for more standardization across laboratories.
Measurement and Outcome | Study: Findings [reference] |
---|---|
Serum 25(OH)D and rickets in children | Meta-analysis: Low 25(OH)D levels associated with established rickets [8] |
Serum 25(OH)D and hip bone mineral density | NHANES III: Positive association [9] |
Supplemental vitamin D and non-vertebral fractures | Meta-analysis: Doses below 400 IU/day did not decrease risk (RR 1.02, 95% CI 0.92–1.15); doses above 480 IU/day decreased risk (RR 0.80, 95% CI 0.72–0.89) [10] |
Supplemental vitamin D and hip fractures | Meta-analysis: Doses below 400 IU/day did not decrease risk (RR 1.09, 95% CI 0.90–1.32); doses above 480 IU/day decreased risk (RR 0.82, 95% CI 0.69–0.97) [10] |
Serum 25(OH)D and lower extremity function | NHANES III: Highest 25(OH)D quintile vs. lowest: faster 8-foot walk test ( p < 0.001) and faster sit-to-stand test ( p = 0.017) [11] |
Supplemental vitamin D and falls | Meta-analysis: Decreased risk with supplementation (OR 0.78, 95% CI 0.64–0.92) [12] |
Serum 25(OH)D and colorectal cancer (CRC) | NHS: Inverse association * ( p = 0.02); OR 0.53 for highest 25(OH)D quintile (95% CI 0.27–1.04) [13] WHI: Inverse association; OR 2.53 for lowest 25(OH)D quintile (95% CI 1.49–4.32) [14] EPIC: Inverse association; OR 1.28 for lowest 25(OH)D quartile (95% CI 1.05–1.56) [15] NHANES III: Inverse association for mortality from CRC; RR 0.28 for highest 25(OH)D tertile (95% CI 0.11–0.68) [16] |
Serum 25(OH)D and prostate cancer | PHS: Increased risk of aggressive cancer for low 25(OH)D (OR 2.1, 95% CI 1.2–3.4) [17] HPFS: No association ( p = 0.20) [18] PLCO: No association ( p trend = 0.05), though higher 25(OH)D may be associated with increased risk of aggressive cancer [19] |
Serum 25(OH)D and breast cancer | NHANES III: Decreased risk of mortality from breast cancer for high 25(OH)D (HR 0.28, 95% CI 0.08–0.93) [16] Meta-analysis: Inverse association ( p trend < 0.001). OR 0.50 for highest 25(OH)D quintile [20] Case-control: Inverse association ( p trend < 0.0001). OR 0.31 for highest 25(OH)D quintile (95% CI 0.24–0.42) [21] |
Serum 25(OH)D and pancreatic cancer | HPFS: Inverse association. RR 0.49 for higher 25(OH)D (95% CI 0.28–0.86) [22] ATBC: Positive association. OR 2.92 for highest 25(OH)D quintile (95% CI 1.56–5.48) [23] |
Total vitamin D intake and pancreatic cancer | Meta-analysis: Decreased risk for >600 IU/day vs. <150 IU/day (RR 0.59, 95% CI 0.40–0.88) [24] |
Serum 25(OH)D and non-Hodgkin lymphoma (NHL) | ATBC: Inverse association for cases diagnosed less than 7 years from baseline ( p trend = 0.01). OR 0.43 for highest vs. lowest 25(OH)D tertile (95% CI 0.23–0.83) [25] HPFS: No association [22] NHANES III: No association for mortality from NHL [16] |
Serum 25(OH)D and lung cancer | Case-control: Positive association for recurrence-free survival in early-stage non-small cell lung cancer patients ( p trend = 0.002). AHR 0.45 for highest 25(OH)D quartile (95% CI 0.24–0.82) [26] Case-control: No association for recurrence-free survival in advanced-stage non-small cell lung cancer patients [27] NHANES III: No association for mortality from lung cancer [16] HPFS: No association [22] Cohort: No association overall, but inverse association for women (RR 0.16, 95% CI 0.04–0.59, p trend <0.001) and younger participants (RR 0.34, 95% CI 0.13–0.90, p trend = 0.04) [28] |
Serum 25(OH)D and total cancer | HPFS: Inverse association. RR 0.83 per increase of 25 nmol/L in predicted 25(OH)D (95% CI 0.74–0.92). Inverse association for total cancer mortality. RR 0.71 per increase of 25 nmol/L in predicted 25(OH)D level (95% CI 0.60–0.83) [22] Cohort: Inverse association for total cancer mortality. HR 0.66 per increase of 25 nmol/L in 25(OH)D (95% CI 0.49–0.89) [29] NHANES III: No association for total cancer mortality [16] |
Supplemental vitamin D and total cancer | RCT: No association [30] RCT: No association [31] |
Serum 25(OH)D and cardiovascular health | NHANES III: Inverse association for cardiac risk factors. For lowest 25(OH)D quartile vs. highest, OR 1.30 for hypertension, OR 1.98 for diabetes mellitus, OR 2.29 for obesity, and OR 1.47 for high serum triglyceride levels ( p < 0.001 for all) [32]. Low 25(OH)D levels had increased self-reported angina, myocardial infarction, and heart failure (OR 1.20, 95% CI 1.01–1.36) [33] Cohort: Inverse association for metabolic syndrome. Inverse association for high hemoglobin A1C, hypertension, and hypertriglyceridemia ( p < 0.004 for all) [34] NHS: Inverse association for incident hypertension. RR 2.67 for low 25(OH)D (95% CI 1.05–6.79) [35] HPFS: Inverse association for incident hypertension. RR 6.13 for low 25(OH)D (95% CI 1.00–37.8) [35] Cohort: Inverse association for cardiovascular-related death. For low 25(OH)D, HR 2.84 for death due to heart failure (95% CI 1.20–6.74), HR 5.05 for sudden cardiac death (95% CI 2.13–11.97) [36] Cohort: Inverse association for cardiovascular-related death. HR 0.76 for highest 25(OH)D quintile (95% CI 0.60–0.95) [37] |
Supplemental vitamin D and blood pressure | RCT: 800 IU/day with 1200 mg/day of calcium decreased SBP by 13 mmHg and heart rate by 4 bpm compared to calcium alone ( p = 0.02) [38] Review: Studies in Denmark, Taiwan, the UK, and the WHI Study in the US showed no association, though lower doses (∼︀400 IU) of vitamin D were used [39] |
UVB exposure and blood pressure | RCT: UVB exposure decreased both SBP and DBP by 6 mmHg ( p < 0.001) [40] |
Serum 25(OH)D and all-cause mortality | NHANES III: Inverse association. HR 0.95 per increase of 10 nmol/L in serum 25(OH)D (95% CI 0.92–0.98). AHR 1.83 for lowest 25(OH)D quintile (95% CI 1.14–2.94), AHR 1.47 for second lowest quintile (95% CI 1.09–1.97) [41] Cohort: Inverse association. HR 2.08 for lower two 25(OH)D quartiles (95% CI 1.60–2.70) [42] |
Supplemental vitamin D and all-cause mortality | Meta-analysis: Adjusted mean daily dose of 528 IU associated with decreased mortality (RR 0.93, 95% CI 0.87–0.99) [43] |
* Inverse association: higher 25(OH)D levels were associated with lower risk.
nmol/L | ng/mL |
---|---|
30 | 12 |
50 | 20 |
75 | 30 |
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here